322 related articles for article (PubMed ID: 28011500)
21. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract][Full Text] [Related]
22. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in patients with advanced renal cell carcinoma.
Muriel López C; Esteban E; Berros JP; Pardo P; Astudillo A; Izquierdo M; Crespo G; Sanmamed M; Fonseca PJ; Martínez-Camblor P
Clin Genitourin Cancer; 2012 Dec; 10(4):262-70. PubMed ID: 22959659
[TBL] [Abstract][Full Text] [Related]
24. Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Bilen MA; Zurita AJ; Ilias-Khan NA; Chen HC; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY; Tannir NM
Oncologist; 2015 Oct; 20(10):1140-8. PubMed ID: 26306901
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
26. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
[TBL] [Abstract][Full Text] [Related]
27. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
28. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
29. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
30. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
31. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
32. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
33. Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer.
Kim BH; Sohn JC; Ha JY; Park CH; Choe MS; Jung HR; Kim CI
Urol Int; 2015; 94(2):137-43. PubMed ID: 25138147
[TBL] [Abstract][Full Text] [Related]
34. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
35. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
[TBL] [Abstract][Full Text] [Related]
36. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D' Alterio C; Portella L; Ottaiano A; Rizzo M; Carteni G; Pignata S; Facchini G; Perdona S; Di Lorenzo G; Autorino R; Franco R; La Mura A; Nappi O; Castello G; Scala S
Curr Cancer Drug Targets; 2012 Jul; 12(6):693-702. PubMed ID: 22463589
[TBL] [Abstract][Full Text] [Related]
37. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
38. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]